05:53 PM EDT, 03/13/2024 (MT Newswires) -- Corbus Pharmaceuticals ( CRBP ) filed a registration statement Wednesday for the potential sale of up to $300 million of securities from time to time.

The filing covers common stock, preferred stock, debt securities, warrants, subscription rights and units.

Unless otherwise stated in a prospectus supplement, the company plans to use the net proceeds for general corporate purposes.

The company also registered a prospectus for the sale of up to $150 million of its common stock under a sales agreement with Jefferies. Proceeds will be used for continued development of CRB-701, CRB-601, CRB-913 and other pre-clinical compounds, Corbus added.

The company shares were down more than 3% in recent after-hours activity.

Price: 45.5, Change: -1.58, Percent Change: -3.36